Table 1.

The studies evaluating the association between EREG expression and survival in human cancers

Type of cancer	Method	Cutoff value	Number of points	Survival for EREG positive	Reference
NSCLC	IHC	≥ score 100a	356	Poor*	43
Lung adenocarcinoma	qRT-PCR	≥ median	119	Poorb	49
Bladder cancer	qRT-PCR	First cutoff: 2.4 and second cutoff: 4.8c	73	Poor	41
Oral squamous cell carcinoma	qRT-PCR	≥0.1	30	Poor	45
Glioblastoma	IHC	≥ score 3d	73	Poor	54

Notes: In all studies, overall survival was analyzed by the Kaplan–Meier method, and comparison between subgroups was examined by the log-rank test.

^aThe staining score was quantified on the basis of staining intensity and extension (intensity × extension);

^bcox regression analysis was also performed, and the hazard ratio, adjusted by tumor stage, was 8.71 (95% CI: 1.90–39.80);

^cthe first-cutoff point was median, and the second-cutoff point was arbitrarily chosen;

^dIHC positivity was determined according to the total score (intensity score + proportional score);

^*P=0.054 for the difference of overall survival, whereas the difference was more evident (P=0.014) after correction for differences in covariates (age, pathological nodal, tumor stage, and histological subtype).

Abbreviations: EREG, epiregulin; NSCLC, non-small-cell lung cancer; IHC, immunohistochemistry; CI, confidence interval; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.